Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 12/20 | 0.47 |
| ▸ | MAOB | P27338 | 12/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15532807 | 0.91 | CRBN (0.47) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL4185902 | 0.85 | HRH3 (0.53) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL28778391 | 0.82 | CA9 (0.54) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL29754348 | 0.82 | CA9 (0.54) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL4184334 | 0.80 | CA9 (0.51) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL29594795 | 0.80 | CA9 (0.51) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL4185512 | 0.79 | HTR1A (0.55) | DRD2DRD4 | |
| SCHEMBL15544884 | 0.78 | MAOA (0.49) | MAOAMAOB | |
| SCHEMBL26604815 | 0.77 | MAOB (0.47) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL26604804 | 0.76 | MAOB (0.47) | DRD2ADRA1DSLC6A4ADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008150848-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2008-12-11 | — | — | WO | disclosed |
| US-7244726-B2 | Heterocyclic compounds possessing affinity at 5HT1 -type receptors and use thereof in therapy | GLAXO GROUP LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| EP-1476444-B1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-20050085458-A1 | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | disclosed |
| EP-1476444-A1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068772-A1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | HTR5A, CRH, CYP17A1 | DRD2 24/4885ADRA1D 191/4885SLC6A4 124/4885 |
| US-20050085458-A1 | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy | HTR3C, HTR1A, HTR2C | DRD2 70/4885ADRA1D 140/4885SLC6A4 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.